Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed as mild to moderate COVID-19 infection with positive PCR test and symptoms (Ct \< 35)~* Parents and patients comprehend and welling to participate in this study.~* Agree to the collection of nasal swabs per day as protocol.~Exclusion Criteria:~* Patients evaluated as severe or critically severe type of COVID-19 infection (Individuals who have SpO2 \<94% on room air, oxygen treatment is necessary, respiratory failure, septic shock, and/or multiple organ dysfunction).~* Patients with comorbidities~* Decline to participate by parents or children~* Allergy to any study medication or usage of any kind of interferon treatment within 14 days before test~* Children cannot tolerate the inhalation treatment~* Any situation where the program cannot be carried out safely.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Intervention: Inhaled Interferon α2b (Type: EXPERIMENTAL): Inhaled Interferon α2b (10U/ml)
- Intervention: Standard of Care (Type: OTHER): Standard of care treatment will be provided according to management guideline.

Based on this trial design, predict the completion outcome and termination type (if applicable).